In addition, tumor‐specific CD4+ and CD8+ T cells increase phosphoenolpyruvate (PEP) production by overexpressing phosphoenolpyruvate carboxykinase 1 (PCK1), thereby inhibiting sarco/ER Ca2+‐ATPase (SERCA) activity. This evidence concerns the gene CD8A and neoplasm.